Skip to content

BubR1 Orchestrates Insulin Receptor Endocytosis to Promote Cutaneous Squamous Cell Carcinogenesis

BubR1 Orchestrates Insulin Receptor Endocytosis to Promote Cutaneous Squamous Cell Carcinogenesis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115428
Enrollment
Unknown
Registered
2025-12-25
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous squamous cell carcinoma (cSCC)

Interventions

adjacent tissue:None

Sponsors

The Fourth Hospital of Changsha (Integrated Traditional Chinese and Western Medicine Hospital of Changsha)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with pathologically confirmed cutaneous squamous cell carcinoma (cSCC); 2. Age 18 years and older, regardless of gender; 3. Planning surgical resection and able to provide adequate tumor and adjacent tissue samples; 4. Signed informed consent and voluntarily participated in this study; 5. No prior radiotherapy, chemotherapy, or targeted therapy was received.

Exclusion criteria

Exclusion criteria: 1. Patients with concurrent malignancies; 2. Patients who have received preoperative treatment that may affect tumor tissue characteristics; 3. Patients with severe medical illnesses (e.g., severe heart, liver, or kidney dysfunction, infection, etc.); 4. Pregnant or lactating women; 5. Patients who are unable to cooperate with the study requirements or refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
BubR1 mRNA relative level;

Countries

China

Contacts

Public ContactWu Zhiqiang

The Fourth Hospital of Changsha (Integrated Traditional Chinese and Western Medicine Hospital of Changsha)

38459374@qq.com+86 731 8894 2016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026